Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Exparel, Posimir. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 16, 2026, FDA lists 3 applications for Bupivacaine (sold as Exparel, Posimir), first approved Oct 28, 2011, with 3 new uses approved and 1 published complete response letter.
First approved: Oct 28, 2011
Applications: 3
New uses approved: 3
Complete response letters: 1
Medicare spending, 2025: $44K
First approved in the EU: Nov 16, 2020
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Bupivacaine HCL
Part B
$28K
-91%
55,247
Bupivacaine HCl
Part D
$15K
-4%
522
Marcaine
Part D
$0K
-22%
27
Sensorcaine
Part D
$0K
-100%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
BUPIVACAINE 0.25% 125 MG/50 ML VL: $0.048 per MLGeneric · +3% in a year
BUPIVACAINE 0.25% VIAL: $0.048 per MLGeneric · +3% in a year
BUPIVACAINE 0.5% 250 MG/50 ML VL: $0.086 per MLGeneric · +6% in a year
BUPIVACAINE 0.5% VIAL: $0.086 per MLGeneric · +6% in a year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA